AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) (“Apogee”) announce they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma. The acquisition complements AbbVie’s existing immunology portfolio and accelerates AbbVie’s clinical presence in the respiratory space. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. The transaction values Apogee at a total equity value of approximately $10.9 billion.
Read the full article: AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio //
Source: https://www.prnewswire.com/news-releases/abbvie-to-acquire-apogee-therapeutics-deepening-immunology-portfolio-302806296.html